Johnson & Johnson (JNJ) to acquire Omrix Biopharmaceuticals (OMRI) for $438M ($25/share), an...

|About: Johnson & Johnson (JNJ)|By:, SA News Editor

Johnson & Johnson (JNJ) to acquire Omrix Biopharmaceuticals (OMRI) for $438M ($25/share), an 18% premium. OMRI's lead product is its fibrin blood-clotting pad, which controls surgical bleeding, and which it claims is superior to JNJ's Surgicel. (PR)